Home > Documents in Process > Prospective associations of blood-based biomarkers of neurodegenerative diseases with cognitive performance in a cohort of patients with chronic coronary syndrome. > print

001     282603
005     20251211161559.0
024 7 _ |a 10.1177/13872877251389147
|2 doi
024 7 _ |a pmid:41252287
|2 pmid
024 7 _ |a 1387-2877
|2 ISSN
024 7 _ |a 1875-8908
|2 ISSN
037 _ _ |a DZNE-2025-01361
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lohner, Valerie
|0 P:(DE-2719)2811856
|b 0
245 _ _ |a Prospective associations of blood-based biomarkers of neurodegenerative diseases with cognitive performance in a cohort of patients with chronic coronary syndrome.
260 _ _ |a Amsterdam
|c 2025
|b IOS Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765466052_17917
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a In a cohort of persons with chronic coronary syndrome, we investigated associations of blood-based biomarkers of neurodegenerative diseases with cognitive scores and mild cognitive impairment (MCI) after ten years. Biomarker levels were measured in baseline samples of serum (glial fibrillary acid protein, neurofilament light chain (NfL), phosphorylated tau181; n = 363) or plasma (amyloid-β42/40-ratio, total-tau; n = 232). Cognitive scores and MCI were measured at ten-year follow-up using the Cognitive Telephone Screening Instrument. At follow-up, 14.7% had MCI. The amyloid-β42/40-ratio was predictive of cognitive scores, while NfL was associated with increased risk of MCI, suggesting that these biomarkers might be utilized for risk stratification.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a amyloid-beta ratio
|2 Other
650 _ 7 |a biomarkers of neurodegenerative diseases
|2 Other
650 _ 7 |a chronic coronary syndrome
|2 Other
650 _ 7 |a cognition
|2 Other
650 _ 7 |a epidemiology
|2 Other
650 _ 7 |a mild cognitive impairment
|2 Other
650 _ 7 |a neurofilament light chain
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Peptide Fragments
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 7 |a Glial Fibrillary Acidic Protein
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: blood
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: psychology
|2 MeSH
650 _ 2 |a Neurofilament Proteins: blood
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: blood
|2 MeSH
650 _ 2 |a tau Proteins: blood
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: blood
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: complications
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Peptide Fragments: blood
|2 MeSH
650 _ 2 |a Glial Fibrillary Acidic Protein: blood
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
650 _ 2 |a Cognition: physiology
|2 MeSH
700 1 _ |a Perna, Laura
|b 1
700 1 _ |a Schöttker, Ben
|b 2
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 3
|u dzne
700 1 _ |a Kliegel, Matthias
|b 4
700 1 _ |a Brenner, Hermann
|b 5
700 1 _ |a Mons, Ute
|b 6
773 _ _ |a 10.1177/13872877251389147
|g Vol. 108, no. 4, p. 1507 - 1513
|0 PERI:(DE-600)2070772-1
|n 4
|p 1507 - 1513
|t Journal of Alzheimer's disease
|v 108
|y 2025
|x 1387-2877
856 4 _ |u https://pub.dzne.de/record/282603/files/DZNE-2025-01361_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/282603/files/DZNE-2025-01361_Restricted.pdf?subformat=pdfa
|x pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2812234
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21